Aurinia Pharmaceuticals Inc. AUPH
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis ("LN"). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor ("BAFF") and a proliferation-inducing ligand ("APRIL") for the potential treatment of autoimmune diseases.
Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States ("U.S."), and Aurinia sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), for the European and Japanese market.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M | $45.6M | $50.1M | $318.0K | $463.0K | $418.0K | $173.0K |
| Cost of revenue | $32.7M | $28.2M | $14.1M | $5.7M | $1.1M | $0 | $0 | — | — | — |
| Gross profit | $250.4M | $206.9M | $161.4M | $128.4M | $44.5M | $50.1M | $318.0K | — | — | — |
| R&D | $32.5M | $20.8M | $49.6M | $45.0M | $51.1M | $50.3M | $52.9M | $41.4M | — | — |
| SG&A | $101.8M | $172.0M | $195.0M | $196.4M | $173.5M | $97.3M | $22.3M | $13.7M | — | — |
| Total operating expenses | $178.1M | $239.8M | $267.2M | $245.5M | $226.3M | $154.4M | $91.3M | $55.7M | — | — |
| Operating income | $104.9M | -$4.7M | -$91.7M | -$111.5M | -$180.7M | -$104.3M | -$90.9M | -$55.2M | -$46.9M | -$25.0M |
| Interest expense | $4.3M | $4.8M | $2.8M | $0 | $0 | — | — | — | — | — |
| Pre-tax income | $114.2M | $7.4M | -$77.5M | -$106.4M | -$180.2M | -$102.8M | -$88.2M | -$53.0M | — | — |
| Income tax | $173.0M | $1.7M | $551.0K | $1.8M | $760.0K | $94.0K | $144.0K | $73.0K | — | — |
| Net income | $287.2M | $5.8M | -$78.0M | -$108.2M | -$181.0M | -$102.7M | -$88.4M | -$53.1M | -$70.8M | -$23.3M |
| EPS, basic | 2.14 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 | -0.95 | — | — | — |
| EPS, diluted | 2.07 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 | -0.95 | -0.63 | — | — |
| Shares, diluted (wtd. avg.) | $138.7M | $146.2M | $143.2M | $141.9M | $129.4M | $118.5M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $80.2M | $83.4M | $48.8M | $94.2M | $231.9M | $272.4M | $306.0M | $118.0M | $165.6M | — |
| Inventory | $45.7M | $39.2M | $39.7M | $24.8M | $19.3M | $13.9M | $0 | — | — | — |
| Total current assets | $492.0M | $446.6M | $424.8M | $442.5M | $513.3M | $419.4M | $315.1M | — | — | — |
| Property, plant and equipment | $2.1M | $2.7M | $3.4M | $3.6M | $4.4M | $4.8M | $93.0K | — | — | — |
| Other intangibles | $3.8M | $4.4M | $5.0M | $6.4M | $8.4M | $9.3M | $8.9M | — | — | — |
| Total assets | $751.6M | $550.6M | $548.1M | $470.9M | $543.4M | $463.7M | $324.3M | $145.9M | $189.8M | $57.0M |
| Accounts payable | $3.3M | $5.2M | $4.3M | $40.0M | $34.9M | $24.8M | $11.2M | — | — | — |
| Total current liabilities | $93.7M | $97.8M | $77.2M | $46.1M | $40.6M | $32.0M | $11.3M | — | — | — |
| Total liabilities | $170.3M | $173.2M | $170.1M | $65.4M | $64.3M | $55.9M | $25.7M | — | — | — |
| Retained earnings | -$649.4M | -$936.6M | -$942.3M | -$864.3M | -$756.1M | -$575.2M | -$472.5M | — | — | — |
| Total equity | $581.3M | $377.5M | $378.0M | $405.4M | $479.1M | $407.8M | $298.6M | $135.7M | $177.9M | $36.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $135.7M | $44.4M | -$33.5M | -$79.5M | -$157.7M | -$69.9M | -$63.6M | -$51.6M | — | — |
| Depreciation and amortisation | $19.4M | $19.4M | $11.6M | $2.7M | $2.8M | $1.4M | $33.0K | $20.0K | — | — |
| Stock-based compensation | $14.7M | $31.6M | $45.3M | $32.3M | $31.2M | $17.5M | $7.4M | $6.9M | — | — |
| Investing cash flow | -$32.8M | $39.3M | -$6.7M | -$60.6M | -$103.9M | -$158.2M | $7.8M | -$65.0K | — | — |
| Financing cash flow | -$106.1M | -$49.1M | -$5.1M | $2.4M | $221.1M | $194.4M | $243.9M | $4.0M | — | — |
| Buybacks | $98.2M | $40.2M | $0 | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001600620-26-000039.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |